Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
SYDNEY, AU, Feb 10, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas. The data analysis found that Asia Pacific has been the fastest-growing region for Phase 1 trials in the last ten years, reaching a share of 58% in 2022, with China leading the Phase I trials globally.
According to the report, titled "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", in 2022 Asia Pacific accounted for a 58% share of the approximately 3,600 Phase I trials initiated globally in 2022. The report found that Asia Pacific has been the fastest growing region for Phase 1 trials in the last ten years with a 10Y CAGR of 18%. Between 2018 and 2022, the region has had consistent performance and has been maintaining its majority share since 2018, with a peak of 61% share achieved in the year 2021. Mainland China, Australia, South Korea, Japan and India were the top five Asian locations, and together contribute over 50% of the global phase I trials.
One of the key reasons why Asia Pacific is in demand is that it has the shortest patient enrolment duration and fastest recruitment rate. Asia Pacific region has a much wider patient base which expedites the patient time recruitment process and shortens the trial duration enabling initiation and completion of trials.
The report found that Asia Pacific also leads phase I trials across the top therapeutic areas. Oncology, infectious disease, CNS, cardiovascular and metabolic disorders are the top therapeutic areas of Phase I trials across the top Asian locations of China, Australia, South Korea, Japan and India. Of all the five locations put together, China occupies the major share (>80%) of phase I trials in all the top therapeutic areas considered together.
View "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", the new report by Novotech, on this link: https://tinyurl.com/novotech-global-report
See the report for Phase 1 location and therapeutic area analysis including: - IMMUNOMODULATORY THERAPY - IMMUNO-ONCOLOGY - ADOPTIVE CELL THERAPY - ALLOGENIC, AUTOLOGOUS, STEM CELL AND REGENERATIVE MEDICINE - DNA AND RNA - VACCINES - MULTI-SPECIFIC MONOCLONAL ANTIBODY - MICROBIOME
Cell & Gene
The latest data also shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region. The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021. China shows a 15% faster growth rate than the ROW. After oncology, the majority of cell & gene trials are in infectious diseases, CNS, and cardiovascular diseases. In addition, the Asia Pacific is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022.
European expansion - global footprint
Novotech offers a unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. Novotech recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.
Award recognition
Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, has been awarded the Asia-Pacific Cell & Gene Therapy Clinical Trials Excellence award and selected for the Asia-Pacific Contract Research Organization Company of the Year Award. The company has signed 45 Leading Site Partnership agreements over the last 3 years.
About Novotech (Novotech-CRO.com)
Novotech is internationally recognized as the leading Asia Pacific centred biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2700 staff working across offices in 20 geographies. For more information visit https://novotech-cro.com/contact
Media Contact David James E: communications@novotech-cro.com AU: +61 2 8218 2144 USA: +1 415 951 3228 Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 TOYOTA GAZOO Racing Set for Spa spectacle May 02, 2025 19:29 JST
|  Toyota Mobility Foundation, Bangkok Metropolitan Administration, UN-Habitat, Asian Institute of Technology and Toyota Motor Thailand Sign a Letter of Intent (LOI) to Launch the TRUST Project for Road Safety in Thailand May 01, 2025 17:48 JST
|  Katalon Officially Launches TrueTest(TM) - The First AI-Native Testing System That Thinks Like a Tester and Learns from Users Apr 30, 2025 17:20 JST
|  Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star Apr 30, 2025 14:17 JST
|  Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of Large Car Ferry KEYAKI in Shimonoseki Apr 29, 2025 17:24 JST
|  NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally Apr 28, 2025 16:03 JST
| NEC achieves Japan's longest terrestrial wireless optical communication over 10 km Apr 25, 2025 17:50 JST
|  Olympus Appoints New CEO Apr 25, 2025 15:30 JST
|  DENSO Announces Year-End Financial Results Apr 25, 2025 12:17 JST
|  DENSO and DELPHY Sign Memorandum of Understanding to Develop Data-Driven Smart Horticulture Apr 24, 2025 18:43 JST
|  MyJCB App Wins "iF DESIGN AWARD 2025" Apr 24, 2025 17:00 JST
|  Fujitsu launches new company 1FINITY to strengthen network products business
Apr 24, 2025 16:24 JST
|  MHIEC Completes Renovation of Core Facilities for Arita Municipal Recycle Plaza in Saga Prefecture Apr 24, 2025 15:01 JST
|  NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business Apr 24, 2025 10:23 JST
|  MHI Thermal Systems Wins German Red Dot Design Award 2025 Apr 24, 2025 10:11 JST
|  ULVAC Develops Dilution Refrigerator for Quantum Computers Apr 24, 2025 09:30 JST
|  Fujitsu expands strategic collaboration with Supermicro to offer total generative AI platform Apr 23, 2025 11:55 JST
|  Furuya Metal and Asahi Kasei Embark on Demonstration Trial Regarding Recycling of Metals for Chlor-alkali Electrolysis Cells and Electrodes Apr 23, 2025 11:00 JST
|  A Decade of Olympus India's Commitment to Community Welfare Apr 22, 2025 13:00 JST
|  Fujitsu and RIKEN develop world-leading 256-qubit superconducting quantum computer Apr 22, 2025 11:37 JST
|
More Latest Release >>
|